MedTrace Logo

Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology

NCT03526809 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2018-05-16

No results posted yet for this study

Summary

Patients with known ovarian cancer will be imaged up to four times with FDG-PET, C13 MRI and other novel MRI techniques during their treatment course including: before the start of any treatment (with optional repeat scanning), after the first dose of chemotherapy (optional), after the third dose of chemotherapy (optional) and after surgery (optional). Imaging findings will be compared to biological properties of cancer tissue samples.

Conditions

Interventions

DIAGNOSTIC_TEST

MRI scan and FDG-PET scan

Scanning with MRI and FDG-PET

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-01
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03526809 on ClinicalTrials.gov